论文部分内容阅读
美国最新的小儿麻痹症疫苗据美国出版的最新一期《药物与治疗信息》(1988年5月6日)报道,该国食物与药品管理局最近已批准一种新型的脊髓灰质尖疫苗用于免疫。新疫苗可经注射途径应用,较美国以往生产的任何一种灭活脊髓灰质尖(IPV)更为有效。目前生产这种新疫苗的厂家有二,Connaught和脊髓Merieux。活的口服疫苗(OPV)自1960年初以来,一直是人们喜爱的常规免疫剂。其优点是使用方便,有较多的免疫原,可诱导胃肠道的免疫性,可通过未接受过免疫的易感接触使疫苗病毒扩散以增强免疫力,且售价低。其缺点是,好多年在美国发生的小儿麻
New polio vaccine in the United States According to the latest issue of Drugs and Treatment Information published in the United States (May 6, 1988), the United States Food and Drug Administration recently approved a new polio vaccine for use in Immune. The new vaccine can be administered via the injection route and is more effective than any previously inactivated poliovirus (IPV) in the United States. There are currently two manufacturers that produce this new vaccine, Connaught and Spinal Cord Merieux. The live oral vaccine (OPV) has been a popular conventional immunizing agent since the early 1960s. The advantage is easy to use, more immunogen, can induce gastrointestinal immunity, vaccination virus can be spread through non-immune susceptible contacts to enhance immunity, and the price is low. The downside is that for many years in the United States happened to children’s numbness